Yemin Wang

List of Publications by Year
in descending order

23	1,027	516710 16	794594 19
papers	citations	h-index	g-index

27	27	27	1827
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ARID1A-mutated ovarian cancers depend on HDAC6Âactivity. Nature Cell Biology, 2017, 19, 962-973.	10.3	173
2	Dual loss of the <scp>SWI</scp>/<scp>SNF</scp> complex <scp>ATPases SMARCA4</scp>/<scp>BRG1</scp> and <scp>SMARCA2</scp>/<scp>BRM</scp> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2016, 238, 389-400.	4.5	169
3	The histone methyltransferase <scp>EZH2</scp> is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2017, 242, 371-383.	4.5	78
4	Class I <scp>HDAC</scp> inhibitors enhance <scp>YB</scp> â€1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	4.5	78
5	DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. American Journal of Surgical Pathology, 2019, 43, 628-638.	3.7	62
6	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. Neoplasia, 2015, 17, 650-660.	5.3	59
7	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clinical Cancer Research, 2018, 24, 1932-1943.	7.0	51
8	p53 Is Positively Regulated by miR-542-3p. Cancer Research, 2014, 74, 3218-3227.	0.9	50
9	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Molecular Cancer Therapeutics, 2018, 17, 2767-2779.	4.1	50
10	SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 467-492.	22.4	47
11	ARID1A regulates R-loop associated DNA replication stress. PLoS Genetics, 2021, 17, e1009238.	3.5	40
12	Recurrent <scp>DICER1</scp> hotspot mutations in endometrial tumours and their impact on <scp>microRNA</scp> biogenesis. Journal of Pathology, 2015, 237, 215-225.	4.5	38
13	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer, 2021, 2, 189-200.	13.2	36
14	DICER1 hotâ€spot mutations in ovarian gynandroblastoma. Histopathology, 2018, 73, 306-313.	2.9	28
15	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthaseâ€“Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Clinical Cancer Research, 2020, 26, 4402-4413.	7.0	21
16	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic Oncology, 2021, 160, 568-578.	1.4	21
17	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. ELife, 2020, 9, .	6.0	19
18	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. PLoS ONE, 2020, 15, e0240412.	2.5	1

#	Article	IF	Citations
19	Fatty acid metabolism and drug resistance to EZH2 inhibition. EBioMedicine, 2022, 77, 103916.	6.1	1
20	Title is missing!. , 2020, 15, e0240412.		0
21	Title is missing!. , 2020, 15, e0240412.		0
22	Title is missing!. , 2020, 15, e0240412.		0
23	Title is missing!. , 2020, 15, e0240412.		0